Nevertheless, the use of the BEAMing technology in LungBEAM, as well as in other studies,13, 19, 43 has shown high sensitivity in detecting EGFR mutations in plasma, which makes it a feasible alternative to tissue‐based mutation analysis in order to guide therapy selection and response evaluation for NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.